| Publication |
Sentence |
Publish Date |
Extraction Date |
Species |
| Nurith Amitai, Svetlana Semenova, Athina Marko. Clozapine attenuates disruptions in response inhibition and task efficiency induced by repeated phencyclidine administration in the intracranial self-stimulation procedure. European journal of pharmacology. vol 602. issue 1. 2009-10-07. PMID:19026629. |
we also explored how chronic treatment with clozapine, an atypical antipsychotic with limited effectiveness on affective and cognitive schizophrenia symptoms, would affect pcp-induced disruptions of icss performance. |
2009-10-07 |
2023-08-12 |
Not clear |
| Adam J Prus, Alan L Pehrson, Scott D Philibin, Jesse T Wood, Sarah A Vunck, Joseph H Porte. The role of M1 muscarinic cholinergic receptors in the discriminative stimulus properties of N-desmethylclozapine and the atypical antipsychotic drug clozapine in rats. Psychopharmacology. vol 203. issue 2. 2009-10-05. PMID:18685832. |
the discriminative stimulus properties of clozapine (clz) have been studied for decades because it remains the prototype for atypical antipsychotic drug effects and yet is unique in many ways, including increased efficacy in treatment-resistant schizophrenia and in reducing suicidality. |
2009-10-05 |
2023-08-12 |
rat |
| Ling Yan Qi, Mei Hong Xiu, Da Chun Chen, Fan Wang, Therese A Kosten, Thomas R Kosten, Xiang Yang Zhan. Increased serum S100B levels in chronic schizophrenic patients on long-term clozapine or typical antipsychotics. Neuroscience letters. vol 462. issue 2. 2009-10-01. PMID:19539717. |
to examine the potentially differential effect of clozapine compared to typical antipsychotics on serum s100b and the relationship between s100b levels and psychopathology in patients with schizophrenia, 63 physically healthy patients with schizophrenia were compared with 50 age-, sex-matched normal controls. |
2009-10-01 |
2023-08-12 |
Not clear |
| Aude Jacob, Noël Zahr, Jean-Sébastien Hulot, Samia Boussouar, Jeanne Vilain, Stéphanie Lafont-Rapnouil, Franck Schurhoff, Christian Funck-Brentan. Therapeutic drug monitoring of clozapine in a hemodialysed smoking patient with schizophrenia. Therapeutic drug monitoring. vol 31. issue 3. 2009-09-25. PMID:19363462. |
therapeutic drug monitoring of clozapine in a hemodialysed smoking patient with schizophrenia. |
2009-09-25 |
2023-08-12 |
Not clear |
| C J Bachmann, D Lehr, F M Theisen, M Preis. Aripiprazole as an adjunct to clozapine therapy in adolescents with early-onset schizophrenia: a retrospective chart review. Pharmacopsychiatry. vol 42. issue 4. 2009-09-15. PMID:19585394. |
aripiprazole as an adjunct to clozapine therapy in adolescents with early-onset schizophrenia: a retrospective chart review. |
2009-09-15 |
2023-08-12 |
Not clear |
| Lingjun Zuo, Xingguang Luo, John H Krystal, Joyce Cramer, Dennis S Charney, Joel Gelernte. The efficacies of clozapine and haloperidol in refractory schizophrenia are related to DTNBP1 variation. Pharmacogenetics and genomics. vol 19. issue 6. 2009-09-09. PMID:19369910. |
the efficacies of clozapine and haloperidol in refractory schizophrenia are related to dtnbp1 variation. |
2009-09-09 |
2023-08-12 |
Not clear |
| Lingjun Zuo, Xingguang Luo, John H Krystal, Joyce Cramer, Dennis S Charney, Joel Gelernte. The efficacies of clozapine and haloperidol in refractory schizophrenia are related to DTNBP1 variation. Pharmacogenetics and genomics. vol 19. issue 6. 2009-09-09. PMID:19369910. |
the prototypical atypical antipsychotic agent, clozapine, is more efficacious for refractory schizophrenia than the 'typical' antipsychotics, but the mechanism underlying this enhanced efficacy is still under investigation. |
2009-09-09 |
2023-08-12 |
Not clear |
| Lingjun Zuo, Xingguang Luo, John H Krystal, Joyce Cramer, Dennis S Charney, Joel Gelernte. The efficacies of clozapine and haloperidol in refractory schizophrenia are related to DTNBP1 variation. Pharmacogenetics and genomics. vol 19. issue 6. 2009-09-09. PMID:19369910. |
this study aimed to investigate the relationship between the dtnbp1 and the effects of clozapine and haloperidol on refractory schizophrenia. |
2009-09-09 |
2023-08-12 |
Not clear |
| H L Chiang, C C Liu, T J Hwan. Rapid dose-dependent effect of clozapine on a schizophrenic patient's lipid profile. Journal of psychopharmacology (Oxford, England). vol 23. issue 4. 2009-08-18. PMID:18562410. |
the rapid effect of clozapine on lipid profile allows fine-tuning in dose adjustment while treating refractory schizophrenia complicated with drug-related dyslipidaemia but worrying about psychotic rebound during clozapine discontinuation. |
2009-08-18 |
2023-08-12 |
Not clear |
| Jimmi Nielsen, Leslie Foldager, Jonathan M Meye. Increased use of antibiotics in patients treated with clozapine. European neuropsychopharmacology : the journal of the European College of Neuropsychopharmacology. vol 19. issue 7. 2009-08-14. PMID:19356909. |
patients with an icd-10 f20.x were identified from the danish central psychiatric research registry and were linked to the national prescription database to identify schizophrenia patients treated with clozapine from 1996 to 2005(n=3374). |
2009-08-14 |
2023-08-12 |
Not clear |
| Andrea Cipriani, Marianna Boso, Corrado Barbu. Clozapine combined with different antipsychotic drugs for treatment resistant schizophrenia. The Cochrane database of systematic reviews. issue 3. 2009-08-14. PMID:19588385. |
clozapine combined with different antipsychotic drugs for treatment resistant schizophrenia. |
2009-08-14 |
2023-08-12 |
Not clear |
| Andrea Cipriani, Marianna Boso, Corrado Barbu. Clozapine combined with different antipsychotic drugs for treatment resistant schizophrenia. The Cochrane database of systematic reviews. issue 3. 2009-08-14. PMID:19588385. |
although clozapine has been shown to be the treatment of choice in people with schizophrenia that are resistant to treatment, one third to two thirds of people still have persistent positive symptoms despite clozapine monotherapy of adequate dosage and duration. |
2009-08-14 |
2023-08-12 |
Not clear |
| Wen-Yu Hsu, Chien-I Lee, Nan-Ying Chiu, David A Kah. Aripiprazole in treatment-refractory schizophrenia. Journal of psychiatric practice. vol 15. issue 3. 2009-08-04. PMID:19461396. |
clozapine is the first choice antipsychotic medication for treatment-refractory schizophrenia; however, there are some disadvantages in using clozapine. |
2009-08-04 |
2023-08-12 |
Not clear |
| Wen-Yu Hsu, Chien-I Lee, Nan-Ying Chiu, David A Kah. Aripiprazole in treatment-refractory schizophrenia. Journal of psychiatric practice. vol 15. issue 3. 2009-08-04. PMID:19461396. |
a few reports have appeared concerning switching from clozapine to other antipsychotics for treatment-refractory schizophrenia. |
2009-08-04 |
2023-08-12 |
Not clear |
| Wen-Yu Hsu, Chien-I Lee, Nan-Ying Chiu, David A Kah. Aripiprazole in treatment-refractory schizophrenia. Journal of psychiatric practice. vol 15. issue 3. 2009-08-04. PMID:19461396. |
this report describes the case of a 58-year-old female patient with treatment-refractory schizophrenia who was successfully switched from clozapine 300 mg/day to aripiprazole 20 mg/day because of changes in consciousness. |
2009-08-04 |
2023-08-12 |
Not clear |
| Linda M Davies, Thomas R E Barnes, Peter B Jones, Shôn Lewis, Fiona Gaughran, Karen Hayhurst, Alison Markwick, Helen Lloy. A randomized controlled trial of the cost-utility of second-generation antipsychotics in people with psychosis and eligible for clozapine. Value in health : the journal of the International Society for Pharmacoeconomics and Outcomes Research. vol 11. issue 4. 2009-07-22. PMID:18179662. |
to assess whether clozapine is likely to be more cost-effective than other second-generation antipsychotics (sgas) in people with schizophrenia. |
2009-07-22 |
2023-08-12 |
Not clear |
| Michela Nosè, Simone Accordini, Paola Artioli, Francesco Barale, Corrado Barbui, Rossella Beneduce, Domenico Berardi, Gerardo Bertolazzi, Bruno Biancosino, Alfredo Bisogno, Raffaella Bivi, Filippo Bogetto, Marianna Boso, Alberto Bozzani, Piera Bucolo, Marcello Casale, Liliana Cascone, Luisa Ciammella, Alessia Cicolini, Gabriele Cipresso, Andrea Cipriani, Paola Colombo, Barbara Dal Santo, Michele De Francesco, Giorgio Di Lorenzo, Walter Di Munzio, Giuseppe Ducci, Arcadio Erlicher, Eleonora Esposito, Luigi Ferrannini, Farida Ferrato, Antonio Ferro, Nicoletta Fragomeno, Vincenzo Fricchione Parise, Maria Frova, Francesco Gardellin, Nicola Garzotto, Andrea Giambartolomei, Giancarlo Giupponi, Luigi Grassi, Natalia Grazian, Lorella Grecu, Gualtiero Guerrini, Francesco Laddomada, Ermanna Lazzarin, Camilla Lintas, Francesca Malchiodi, Lara Malvini, Livio Marchiaro, Alessandra Marsilio, Massimo Carlo Mauri, Antonio Mautone, Marco Menchetti, Giuseppe Migliorini, Marco Mollica, Daniele Moretti, Serena Mulè, Stylianos Nicholau, Flavio Nosè, Guglielmo Occhionero, Anna Maria Pacilli, Stefania Pecchioli, Mauro Percudani, Ennio Piantato, Carlo Piazza, Francesco Pontarollo, Roger Pycha, Roberto Quartesan, Luciana Rillosi, Francesco Risso, Raffella Rizzo, Paola Rocca, Stefania Roma, Matteo Rossattini, Giuseppe Rossi, Giovanni Rossi, Alessandra Sala, Claudio Santilli, Giuseppe Saraò, Antonio Sarnicola, Francesca Sartore, Silvio Scarone, Tiziana Sciarma, Alberto Siracusano, Stefania Strizzolo, Michele Tansella, Gino Targa, Annamarie Tasser, Rodolfo Tomasi, Rossana Travaglini, Antonio Veronese, Simona Zier. Rationale and design of an independent randomised controlled trial evaluating the effectiveness of aripiprazole or haloperidol in combination with clozapine for treatment-resistant schizophrenia. Trials. vol 10. 2009-07-09. PMID:19445659. |
rationale and design of an independent randomised controlled trial evaluating the effectiveness of aripiprazole or haloperidol in combination with clozapine for treatment-resistant schizophrenia. |
2009-07-09 |
2023-08-12 |
Not clear |
| Michela Nosè, Simone Accordini, Paola Artioli, Francesco Barale, Corrado Barbui, Rossella Beneduce, Domenico Berardi, Gerardo Bertolazzi, Bruno Biancosino, Alfredo Bisogno, Raffaella Bivi, Filippo Bogetto, Marianna Boso, Alberto Bozzani, Piera Bucolo, Marcello Casale, Liliana Cascone, Luisa Ciammella, Alessia Cicolini, Gabriele Cipresso, Andrea Cipriani, Paola Colombo, Barbara Dal Santo, Michele De Francesco, Giorgio Di Lorenzo, Walter Di Munzio, Giuseppe Ducci, Arcadio Erlicher, Eleonora Esposito, Luigi Ferrannini, Farida Ferrato, Antonio Ferro, Nicoletta Fragomeno, Vincenzo Fricchione Parise, Maria Frova, Francesco Gardellin, Nicola Garzotto, Andrea Giambartolomei, Giancarlo Giupponi, Luigi Grassi, Natalia Grazian, Lorella Grecu, Gualtiero Guerrini, Francesco Laddomada, Ermanna Lazzarin, Camilla Lintas, Francesca Malchiodi, Lara Malvini, Livio Marchiaro, Alessandra Marsilio, Massimo Carlo Mauri, Antonio Mautone, Marco Menchetti, Giuseppe Migliorini, Marco Mollica, Daniele Moretti, Serena Mulè, Stylianos Nicholau, Flavio Nosè, Guglielmo Occhionero, Anna Maria Pacilli, Stefania Pecchioli, Mauro Percudani, Ennio Piantato, Carlo Piazza, Francesco Pontarollo, Roger Pycha, Roberto Quartesan, Luciana Rillosi, Francesco Risso, Raffella Rizzo, Paola Rocca, Stefania Roma, Matteo Rossattini, Giuseppe Rossi, Giovanni Rossi, Alessandra Sala, Claudio Santilli, Giuseppe Saraò, Antonio Sarnicola, Francesca Sartore, Silvio Scarone, Tiziana Sciarma, Alberto Siracusano, Stefania Strizzolo, Michele Tansella, Gino Targa, Annamarie Tasser, Rodolfo Tomasi, Rossana Travaglini, Antonio Veronese, Simona Zier. Rationale and design of an independent randomised controlled trial evaluating the effectiveness of aripiprazole or haloperidol in combination with clozapine for treatment-resistant schizophrenia. Trials. vol 10. 2009-07-09. PMID:19445659. |
one third to two thirds of people with schizophrenia have persistent psychotic symptoms despite clozapine treatment. |
2009-07-09 |
2023-08-12 |
Not clear |
| Menahem Krakowski, Pal Czobor, Leslie Citrom. Weight gain, metabolic parameters, and the impact of race in aggressive inpatients randomized to double-blind clozapine, olanzapine or haloperidol. Schizophrenia research. vol 110. issue 1-3. 2009-07-07. PMID:19269139. |
the goal of this study was to assess the effects of clozapine and olanzapine in comparison to the first-generation agent haloperidol on these metabolic parameters in aggressive patients with schizophrenia. |
2009-07-07 |
2023-08-12 |
Not clear |
| Emilio Sacchetti, Alessandro Galluzzo, Paolo Valsecchi, Fabio Romeo, Barbara Gorini, Lewis Warringto. Ziprasidone vs clozapine in schizophrenia patients refractory to multiple antipsychotic treatments: the MOZART study. Schizophrenia research. vol 110. issue 1-3. 2009-07-07. PMID:19269791. |
ziprasidone vs clozapine in schizophrenia patients refractory to multiple antipsychotic treatments: the mozart study. |
2009-07-07 |
2023-08-12 |
Not clear |